Drugs / MB-IMP
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06526208 Comparator | May 2025 → Sep 2026 overdue | anxiety, autism spectrum disorder | Southwest Autism Research & Resource Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-IMP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06526208 ↗ |
| Route | Oral | “is an oil-based tincture that is taken orally.” NCT06526208 ↗ |